Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE)

NCT03407976 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT03407976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03407976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE)
Lead sponsor
University of Utah
Phase
Phase 1
Overall status
Terminated
Start date
June 19, 2018
Completion date
July 2, 2020
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, gastric or gastroesophageal junction (gej) adenocarcinoma, msi-h or dmmr solid tumors, urothelial carcinoma